Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues
S Wang, Y Wang, C Zhu, B Jiang, D Ge, Y Li - Clinical and Translational Oncology, 2024
Objective The primary objective of this study is to explore the significance of
concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in
gastric cancer tissues. Methods Fluorescence in situ hybridization (FISH) and
immunohistochemistry (IHC) methodologies were used to detect HER2 gene
amplification, as well as the expression levels of HER2, p53, and Ki67 proteins,
across a group of 78 gastric cancer cases. Results The expression rate of the HER2 …
concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in
gastric cancer tissues. Methods Fluorescence in situ hybridization (FISH) and
immunohistochemistry (IHC) methodologies were used to detect HER2 gene
amplification, as well as the expression levels of HER2, p53, and Ki67 proteins,
across a group of 78 gastric cancer cases. Results The expression rate of the HER2 …
| • | 1 件目の引用Defucosylated Mouse-Dog Chimeric Anti-Human …  |
 |
 |
 |
 |
[PDF] Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
E Zheng, M Włodarczyk, A Węgiel, A Osielczak… - Frontiers in Surgery, 2024
Over the course of nearly six decades since the inception of initial trials involving 5-
FU in the treatment of mCRC (metastatic colorectal cancer), our progressive
comprehension of the pathophysiology, genetics, and surgical techniques related to
mCRC has paved the way for the introduction of novel therapeutic modalities. These
advancements not only have augmented the overall survival but have also positively
impacted the quality of life (QoL) for affected individuals. Despite the remarkable …
FU in the treatment of mCRC (metastatic colorectal cancer), our progressive
comprehension of the pathophysiology, genetics, and surgical techniques related to
mCRC has paved the way for the introduction of novel therapeutic modalities. These
advancements not only have augmented the overall survival but have also positively
impacted the quality of life (QoL) for affected individuals. Despite the remarkable …
| • | 引用: Current targeted therapy for metastatic colorectal cancer |
|
|
|
|
[PDF] Trop2-targeted therapies in solid tumors: advances and future directions
X Liu, L Ma, J Li, L Sun, Y Yang, T Liu, D Xing, S Yan…
Trophoblast cell surface antigen 2 (Trop2) is overexpressed in a range of solid
tumors and participants in multiple oncogenic signaling pathways, making it an
attractive therapeutic target. In the past decade, the rapid development of various
Trop2-targeted therapies, notably marked by the advent of the antibody-drug
conjugate (ADC), revolutionized the outcome for patients facing Trop2-positive
tumors with limited treatment opinions, such as triple-negative breast cancer (TNBC) …
tumors and participants in multiple oncogenic signaling pathways, making it an
attractive therapeutic target. In the past decade, the rapid development of various
Trop2-targeted therapies, notably marked by the advent of the antibody-drug
conjugate (ADC), revolutionized the outcome for patients facing Trop2-positive
tumors with limited treatment opinions, such as triple-negative breast cancer (TNBC) …
| • | 引用: An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor … |
|
|
|
|
[PDF] Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor …
XT Lin, P Yang, MK Wang, X Huang, B Wang, C Chen… - Frontiers in Pharmacology, 2024
Gastric cancer, the fifth most prevalent cancer worldwide, is often diagnosed in
advanced stages with limited treatment options. Examining the tumor
microenvironment (TME) and its metabolic reprogramming can provide insights for
better diagnosis and treatment. This study investigates the link between TME factors
and metabolic activity in gastric cancer using bulk and single-cell RNA-sequencing
data. We identified two molecular subtypes in gastric cancer by analyzing the distinct …
advanced stages with limited treatment options. Examining the tumor
microenvironment (TME) and its metabolic reprogramming can provide insights for
better diagnosis and treatment. This study investigates the link between TME factors
and metabolic activity in gastric cancer using bulk and single-cell RNA-sequencing
data. We identified two molecular subtypes in gastric cancer by analyzing the distinct …
| • | 引用: Increased expression of highly sulfated keratan sulfate synthesized … |
|
|
|
|
[PDF] Evaluation of Microvascular Density in Glioblastomas in Relation to p53 and Ki67 Immunoexpression
TC Sipos, A Kövecsi, L Kocsis, M Nagy-Bota, Z Pap - International Journal of …, 2024
Glioblastoma is the most aggressive tumor in the central nervous system, with a
survival rate of less than 15 months despite multimodal therapy. Tumor recurrence
frequently occurs after removal. Tumoral angiogenesis, the formation of neovessels,
has a positive impact on tumor progression and invasion, although there are
controversial results in the specialized literature regarding its impact on survival. This
study aims to correlate the immunoexpression of angiogenesis markers (CD34 …
survival rate of less than 15 months despite multimodal therapy. Tumor recurrence
frequently occurs after removal. Tumoral angiogenesis, the formation of neovessels,
has a positive impact on tumor progression and invasion, although there are
controversial results in the specialized literature regarding its impact on survival. This
study aims to correlate the immunoexpression of angiogenesis markers (CD34 …
| • | 引用: Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute … |
|
|
|
|
IDH1 p. R132C 変異を有し進行性に悪性転化した Ollier 病合併多発神経膠腫の 1 例
渡邊元， 藤井雄， 花岡吉亀， 田中美幸， 岩谷舞… - 臨床神経学, 2024
抄録 21 歳男性. 1 歳時に Ollier 病と診断, 15 歳時に偶発的に多発神経膠腫を認めた.
その後増大したため, 3 回摘出術を施行した. 遺伝子解析では IDH1 p. R132C 変異を認め,
病理組織診断では悪性転化を認めた. 集学的治療でも腫瘍は制御されず, 23
歳時に死亡した. Ollier 病は IDH1/2 変異を有す稀な疾患であり, 神経膠腫をしばしば合併
する. しかし, IDH1/2 変異に対する遺伝子解析や長期フォローアップを実施した報告は非常
に限られている. Ollier 病合併神経膠腫では IDH1/2 変異の遺伝子解析は病態解明の一助 …
その後増大したため, 3 回摘出術を施行した. 遺伝子解析では IDH1 p. R132C 変異を認め,
病理組織診断では悪性転化を認めた. 集学的治療でも腫瘍は制御されず, 23
歳時に死亡した. Ollier 病は IDH1/2 変異を有す稀な疾患であり, 神経膠腫をしばしば合併
する. しかし, IDH1/2 変異に対する遺伝子解析や長期フォローアップを実施した報告は非
に限られている. Ollier 病合併神経膠腫では IDH1/2 変異の遺伝子解析は病態解明の一助 …
| • | 引用: IDH 2 and TP 53 mutations are correlated with gliomagenesis in a  |